Breckenridge Pharmaceutical Inc, the US subsidiary of Spain-based Towa International, announced on Monday the launch of Pomalidomide Capsules, a generic version of Pomalyst by Celgene (now Bristol Myers Squibb), within the oncology therapeutic category.

The product was developed in partnership with NATCO Pharma Limited of India.

Pomalidomide Capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma.

The product is available in 1mg, 2mg, 3mg, and 4mg strengths and is distributed primarily through specialty pharmacies and clinics.

Pomalidomide Capsules are available only through a restricted programme called PS-Pomalidomide REMS.